Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

PLIANT THERAPEUTICS, INC. (PLRX)

$1.09 +0.93% NASDAQ: PLRX · 15-min delayed
  • SOUTH SAN FRANCISCO, California
  • Public · NASDAQ: PLRX
  • 49 employees
$71.2MMarket cap
$0Revenue · FY2025
-$149.3MNet income
49Employees
PLRXNASDAQ
2020IPO

About PLIANT THERAPEUTICS, INC.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$0
Net income
-$149.3M
Total assets
$225.2M
Market cap
$71.2M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$156.4M
Operating income
-$156.4M
Income tax
$0
Net income
-$149.3M
EPS (basic)
$-2.43
EPS (diluted)
$-2.43

Balance sheet

Total assets
$225.2M
Current assets
$196.4M
Total liabilities
$44.0M
Current liabilities
$16.4M
Shareholders’ equity
$181.2M

Cash flow

Operating cash flow
-$128.3M
Investing cash flow
$134.3M
Financing cash flow
-$31.7M
Net cash flow
-$25.7M

Statements via Polygon.io (SEC filings)

NASDAQ: PLRX
$1.09 +0.93%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.07 $1.87

52-week range

Market cap
$71.2M
EPS (diluted)
$-2.43
Shares outstanding
65.3M
Open
Day range
Prev close
Volume
IPO date
Jun 3, 2020

Pliant Therapeutics, Inc. (PLRX) Stock Price

  • Reported a net loss of $149.3M in FY2025.
  • Trading 42% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review PLIANT THERAPEUTICS, INC..

Write a review
Newsroom

News about PLIANT THERAPEUTICS, INC.

News & sentiment via Polygon.io

FAQ

Pliant Therapeutics, Inc.: frequently asked questions

Is Pliant Therapeutics, Inc. an American company?

Pliant Therapeutics, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Pliant Therapeutics, Inc. headquartered?

Pliant Therapeutics, Inc. is headquartered in South San Francisco, California, United States.

Is Pliant Therapeutics, Inc. publicly traded?

Yes — Pliant Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol PLRX on the NASDAQ.

What does Pliant Therapeutics, Inc. do?

Pliant Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →